1312 Stock Overview
An investment holding company, engages in the manufacture and sale of prescription drugs in Mainland China, Singapore, Taiwan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Kontafarma China Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.027 |
| 52 Week High | HK$0.048 |
| 52 Week Low | HK$0.026 |
| Beta | 0.060 |
| 1 Month Change | -10.00% |
| 3 Month Change | -18.18% |
| 1 Year Change | -25.00% |
| 3 Year Change | -44.90% |
| 5 Year Change | -83.13% |
| Change since IPO | -87.61% |
Recent News & Updates
Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?
Dec 20
Kontafarma China Holdings Limited's (HKG:1312) Price Is Right But Growth Is Lacking After Shares Rocket 44%
Oct 09Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?
Sep 04Recent updates
Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?
Dec 20Kontafarma China Holdings Limited's (HKG:1312) Price Is Right But Growth Is Lacking After Shares Rocket 44%
Oct 09Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?
Sep 04Here's Why Kontafarma China Holdings Limited's (HKG:1312) CEO Compensation Is The Least Of Shareholders Concerns
May 31There's No Escaping Kontafarma China Holdings Limited's (HKG:1312) Muted Revenues Despite A 61% Share Price Rise
May 24Health Check: How Prudently Does Kontafarma China Holdings (HKG:1312) Use Debt?
Dec 28Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?
Sep 01Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?
Dec 29Health Check: How Prudently Does Tongfang Kontafarma Holdings (HKG:1312) Use Debt?
Sep 15Tongfang Kontafarma Holdings (HKG:1312) Has Debt But No Earnings; Should You Worry?
Apr 20Is Tongfang Kontafarma Holdings (HKG:1312) A Risky Investment?
Nov 04Tongfang Kontafarma Holdings' (HKG:1312) Shareholders Are Down 90% On Their Shares
Feb 18These 4 Measures Indicate That Tongfang Kontafarma Holdings (HKG:1312) Is Using Debt Extensively
Dec 07Shareholder Returns
| 1312 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | 1.9% |
| 1Y | -25.0% | -6.5% | 18.1% |
Return vs Industry: 1312 underperformed the Hong Kong Pharmaceuticals industry which returned -6.5% over the past year.
Return vs Market: 1312 underperformed the Hong Kong Market which returned 18.1% over the past year.
Price Volatility
| 1312 volatility | |
|---|---|
| 1312 Average Weekly Movement | 10.1% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in HK Market | 18.7% |
| 10% least volatile stocks in HK Market | 4.0% |
Stable Share Price: 1312 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1312's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 717 | Feifei Wang | www.kontafarma.com.hk |
Kontafarma China Holdings Limited, an investment holding company, engages in the manufacture and sale of prescription drugs in Mainland China, Singapore, Taiwan, and internationally. It operates in Pharmaceutical Business and Fitness Business segments. The company offers chemical drugs and prescribed traditional Chinese medicines; operates fitness and yoga centers; operates in the franchise business; and provides consultation services for fitness and health activities.
Kontafarma China Holdings Limited Fundamentals Summary
| 1312 fundamental statistics | |
|---|---|
| Market cap | HK$150.89m |
| Earnings (TTM) | -HK$63.24m |
| Revenue (TTM) | HK$836.92m |
0.2x
P/S Ratio-2.4x
P/E RatioIs 1312 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1312 income statement (TTM) | |
|---|---|
| Revenue | HK$836.92m |
| Cost of Revenue | HK$335.76m |
| Gross Profit | HK$501.16m |
| Other Expenses | HK$564.40m |
| Earnings | -HK$63.24m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.011 |
| Gross Margin | 59.88% |
| Net Profit Margin | -7.56% |
| Debt/Equity Ratio | 4.1% |
How did 1312 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 23:27 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kontafarma China Holdings Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|